Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

v3.22.2.2
Net Loss Per Share (Tables)
6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share

The respective “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the periods indicated - is as follows:

 

                                 
   

Three Months Ended

June 30,

   

Six Months Ended

June 30,

 
    2022     2021     2022     2021  
Numerator                                
Net loss - before noncontrolling interest   $ (29,101 )   $ (12,670 )   $ (48,734 )   $ (22,779 )
Net loss attributable to noncontrolling interest     3,576       1,199       6,337       1,877  
Net loss - as reported, attributable to PAVmed Inc.   $ (25,525 )   $ (11,471 )   $ (42,397 )   $ (20,902 )
                                 
Series B Convertible Preferred Stock dividends – earned   $ (70 )   $ (74 )   $ (138 )   $ (149 )
                                 
Net loss attributable to PAVmed Inc. common stockholders   $ (25,595 )   $ (11,545 )   $ (42,535 )   $ (21,051 )
                                 
Denominator                                
Weighted average common shares outstanding, basic and diluted     86,957,352       82,235,397       86,689,857       78,117,637  
                                 
Loss per share                                
Basic and diluted                                
Net loss - as reported, attributable to PAVmed Inc.   $ (0.29 )   $ (0.14 )   $ (0.49 )   $ (0.27 )
Net loss attributable to PAVmed Inc. common stockholders   $ (0.29 )   $ (0.14 )   $ (0.49 )   $ (0.27 )
Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share

 

    2022     2021  
    June 30,  
    2022     2021  
Stock options and restricted stock awards     12,177,406       10,573,530  
Series Z Warrants     11,937,450       15,074,281  
Series W Warrants           381,818  
Series B Convertible Preferred Stock     1,158,950       1,185,685  
Total     25,273,806       27,215,314